SCLC, EXTENSIVE STAGE
Clinical trials for SCLC, EXTENSIVE STAGE explained in plain language.
Never miss a new study
Get alerted when new SCLC, EXTENSIVE STAGE trials appear
Sign up with your email to follow new studies for SCLC, EXTENSIVE STAGE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First-in-Human trial launches for Off-the-Shelf CAR-NK therapy against tough cancers
Disease control Recruiting nowThis early-stage trial is testing a new cell therapy called NEUK203-13 for people with advanced small cell lung cancer or other neuroendocrine tumors that have not responded to standard treatments. The therapy uses immune cells (NK cells) made from stem cells and engineered to ta…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy aims to extend remission in aggressive lung cancer
Disease control Recruiting nowThis trial tests whether adding the drug niraparib to standard maintenance therapy can help people with a specific type of advanced small cell lung cancer (SLFN11-positive) stay cancer-free longer. About 44 participants will receive niraparib pills plus an anti-PD-L1 antibody aft…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered immune cells take on tough lung cancer
Disease control Recruiting nowThis study tests a new treatment called CAR-NK cells, which are immune cells engineered to recognize and attack cancer. The trial enrolls 60 adults with small cell lung cancer that has come back or not responded to standard treatments. Participants receive the cells along with ch…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug combo aims to keep advanced lung cancer in check
Disease control Recruiting nowThis phase 2 trial tests whether adding golidocitinib to standard PD-1 inhibitor maintenance therapy can help people with extensive-stage small cell lung cancer (SCLC) stay progression-free longer. Twenty adults who have not yet been treated for their advanced SCLC will receive t…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Radioactive drug plus immunotherapy shows promise for tough lung cancer
Disease control Recruiting nowThis early-phase study tests a combination of a radioactive drug ([225Ac]Ac-DOTATATE) and an immunotherapy (tislelizumab) as maintenance therapy for people with extensive-stage small cell lung cancer that has a specific marker (SSTR). The goal is to see if this combination is saf…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE1 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New daily pill shows promise for tough cancers
Disease control Recruiting nowThis study tests a new tablet called ABP1011T in people with advanced solid tumors, including small cell lung cancer and others like esophageal or bladder cancer. Participants take one pill daily in 21-day cycles. The goal is to see if the drug can shrink tumors and how safe it i…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: Shanghai AB PharmaTech Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New combo aims to keep advanced lung cancer in check
Disease control Recruiting nowThis study tests whether combining the immunotherapy drug adebrelimab with the chemotherapy drug etoposide (as capsules) can help control extensive-stage small cell lung cancer after initial treatment. About 32 adults in China will receive the combination every three weeks until …
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Virus therapy takes on tough lung cancer
Disease control Recruiting nowThis study tests a new treatment for advanced small cell lung cancer that has stopped responding to standard therapies. The treatment combines an oncolytic virus (Olvi-Vec) with standard chemotherapy drugs. The goal is to see if this combination is safe and can shrink tumors in 2…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE1, PHASE2 • Sponsor: Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New PET scan probe could sharpen lung cancer detection
Diagnosis Recruiting nowThis study is testing a new radioactive probe called PFD3, used with a PET/CT scan, to see if it can better find and assess small cell lung cancer (SCLC) by targeting a protein called DLL3 found on cancer cells. About 30 adults with SCLC will receive both a standard FDG scan and …
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE1, PHASE2 • Sponsor: Peking University First Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC